New contrast agent for heart MRI (DTPA-PPDA Mn (II)) was designed and synthesized for the first time.
Phantom experiments revealed good degree of amplification of T1-weighted images.
DFT calculations showed higher complexation constant than for DTPA Mn (II).
Molecular docking revealed high affinity to a heart-type fatty acid binding protein.